GICS Sector : Healthcare
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally.It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery.
RxSight reported fourth-quarter 2025 sales of $32.6 million, a 19% year-over-year decline due to lower LDD sales. However, LAL sales remained steady at $28.2 million, accounting for 86% of total company sales. The gross margin improved to 77.5% in Q4 2025 compared to 71.6% in the year-ago period. For the full year 2025, sales increased 4% year-over-year to $134.5 million, driven by a 12% increase in LAL sales. The company's gross profit margin for 2025 was 76.6%, up from 70.7% in 2024. RxSight's actual EPS for Q4 2025 came in at -$0.03, beating estimates of -$0.23.
Publication Date: Mar -08
The company provided 2026 revenue guidance of $120 million to $135 million, implying a year-over-year decline of approximately 5% at the midpoint of the range. Gross margin guidance for 2026 is between 70% to 72%. According to Mark Wilterding, the team is "currently focused on building relationships with key opinion leaders and collecting country-specific clinical data to position the company for more meaningful international sales in 2027 and beyond."
RxSight's current valuation metrics indicate a P/S Ratio of 2.36 and an EV/EBITDA of -7.78. The company's ROE and ROIC are -14.05% and -16.81%, respectively. Analysts estimate next year's revenue growth at 9.5%. With the current valuation multiples, the market seems to be pricing in a moderate growth rate, but the company's improving gross margin and steady LAL sales provide a positive outlook.
Ronald Kurtz discussed the company's focus on improving utilization within the existing installed base and expanding access to the technology. The company is also seeing early success stories from its commercial pivot, with a structured program aimed at individual practices and needs. Kurtz believes this will continue as they expand into more clinical sites.
RxSight is making progress in its international expansion, with regulatory approvals in several countries and a growing footprint. The company notes that the international market is about double the size of the US market. Kurtz also mentioned that the company will continue to innovate on the lens and LDD sides, as well as other ancillary devices associated with their technology.
Short Interest in RxSight, Inc. (NASDAQ:RXST) Expands By 29.3%
Mar -03
RxSight, Inc. (RXST) Q4 2025 Earnings Call Transcript
Feb -26
RxSight, Inc. (RXST) Reports Q4 Loss, Beats Revenue Estimates
Feb -26
RxSight, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
Feb -11
Head to Head Analysis: RxSight (NASDAQ:RXST) vs. Edap Tms (NASDAQ:EDAP)
Feb -09
Baillie Gifford & Co. Raises Stock Holdings in RxSight, Inc. $RXST
Jan -26
RxSight, Inc. (NASDAQ:RXST) Given Consensus Rating of “Reduce” by Analysts
Jan -26
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc. - RXST
Jan -22
RxSight's Light Adjustable Lenses and related capital equipment are driven by increasing demand for cataract surgeries, growing adoption of premium intraocular lenses, and rising awareness of personalized vision correction. Additionally, the company's proprietary technology and expanding sales network contribute to its 10.45% growth.
A type of intraocular lens that can be adjusted after implantation to achieve optimal vision
A data analytics platform that provides insights and visualization tools for ophthalmologists
A suite of surgical planning and guidance tools for ophthalmic surgeons
RxSight, Inc. faces moderate threat from substitutes, as patients may opt for alternative treatments or delay procedures, but the company's innovative technology and strong brand reputation mitigate this risk.
RxSight, Inc. has a diverse customer base, and individual customers do not have significant bargaining power, reducing the risk of price negotiations or demands for customized products.
RxSight, Inc. relies on a few key suppliers for critical components, and while there are alternative suppliers available, the company's dependence on these suppliers gives them some bargaining power.
RxSight, Inc. operates in a highly competitive industry, and new entrants may be attracted to the market, potentially disrupting the company's market share and pricing power.
RxSight, Inc. operates in a highly competitive industry, and intense rivalry among existing players may lead to aggressive pricing, advertising, and innovation, increasing the risk of market share loss.
| Value | |
|---|---|
| Debt Weight | 1.84% |
| Debt Cost | 9.95% |
| Equity Weight | 98.16% |
| Equity Cost | 9.95% |
| WACC | 9.95% |
| Leverage | 1.88% |
Value: 5.6
Growth: 4.0
Quality: 6.3
Yield: 1.0
Momentum: 2.5
Volatility: 7.3
1-Year Total Return ->
Value: 0.0
Growth: 9.7
Quality: 7.1
Yield: 0.0
Momentum: 6.0
Volatility: 2.7
1-Year Total Return ->
Value: 0.2
Growth: 8.0
Quality: 5.9
Yield: 0.0
Momentum: 6.0
Volatility: 3.0
1-Year Total Return ->
Value: 7.7
Growth: 6.6
Quality: 5.3
Yield: 0.0
Momentum: 0.0
Volatility: 1.3
1-Year Total Return ->
Value: 6.6
Growth: 6.2
Quality: 4.5
Yield: 0.0
Momentum: 0.0
Volatility: 3.0
1-Year Total Return ->
Value: 6.2
Growth: 1.8
Quality: 5.5
Yield: 0.0
Momentum: 1.5
Volatility: 4.0
1-Year Total Return ->